# US 2021/0082540 A1 · Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0082540 A1
- Document ID: US20210082540A1
- Status: Published application
- Kind: A1
- Application number: 16/978,903
- Filed: 2019-03-07
- Published: 2021-03-18
- Earliest claimed: 2018-03-08
- Assignees: University of Notre Dame du Lac
- Applicants: University of Notre Dame Du Lac
- Inventors: Steven Buechler
- Web page: https://patentgrep.com/patent/US20210082540A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 70/60: relating to pathologies
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Products, systems, and methods for classifying human colorectal cancer into a consensus molecular subtype (CMS) and for assessing risk of recurrence based on CMS scores and based on risk scores derived from abbreviated gene expression profiles, for determining suitable treatment protocols for human colorectal cancer patients based on the determined CMS classification and based on the determined risk of recurrence, and for administering the suitable treatment protocols.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A method of accurately determining a consensus molecular subtype of a colorectal cancer from a cancer patient, the method comprising:
obtaining an expression level of at least three colorectal cancer RNA transcripts from a first group of genetic elements, the first group of genetic elements comprising genes ENTREZ IDs 6418, 9219, 10855, 3191, 9037, 10079, 83737, 10140, 8313, 54891, 57798, 998, 7105, 23475, 6431, 3725, 81786, 9554, 1602, 57168, 401474, 139322, 1783, 29966, 80183, 8019, 3549, 27330, and 10451;
obtaining an expression level of at least three colorectal cancer RNA transcripts from a second group of genetic elements, the second group of genetic elements comprising genes ENTREZ IDs 5326, 112858, 1057, 6780, 23509, 51497, 430, 171023, 25980, 23475, 22919, 80183, 51526, 28951, 1056, 1846, 644, 9054, 55661, 54894, 58490, and 4212;
obtaining an expression level of at least three colorectal cancer RNA transcripts from a third group of genetic elements, the third group of genetic elements comprising genes 4217, 84666, 8857, 7078, 80150, 4151, 54596, 143458, 84189, 7410, 5937, 25837, 10753, 192134, 201501, 9509, 140828, 84624, 1290, 405753, 1278, 2335, 1295, 3488, 9254, and 155465;
obtaining an expression level of at least three colorectal cancer RNA transcripts from a fourth group of genetic elements, the fourth group of genetic elements comprising genes ENTREZ IDs 23414, 30008, 27295, 2737, 143903, 154810, 11037, 7145, 9590, 5178, 23194, 4256, 10000, 1410, 862, 4286, 83871, 421 1, 165, 6695, 1292, 9353, 4131, 8639, 5549, 547%, 147906, and 8828;
determining, based on the expression level of each of the at least three RNA transcripts from the first group of genetic elements, a first CMS score representative of a probability that the CMS of the colorectal cancer is CMS1;
determining, based on the expression level of each of the at least three RNA transcripts from the second group of genetic elements, a second CMS score representative of a probability that the CMS of the colorectal cancer is CMS2;
determining, based on the expression level of each of the at least three RNA transcripts from the third group of genetic elements, a third CMS score representative of a probability that the CMS of the colorectal cancer is CMS3;
determining, based on the expression level of each of the at least three RNA transcripts from the fourth group of genetic elements, a fourth CMS score representative of a probability that the CMS of the colorectal cancer is CMS4; and
generating a report indicating one or more of:
the first, second, third, and/or fourth CMS scores;
the probability that the CMS of the colorectal cancer is CMS1, CMS2, CMS3, and/or CMS4; and
a treatment protocol specific for the colorectal cancer, wherein one or more of the first, second, third, and/or fourth CMS scores, and the probability that the CMS of the colorectal cancer is CMS1, CMS2, CMS3, and/or CMS4 indicates the treatment protocol specific for the colorectal cancer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the report is visually displayed on a graphical user interface, the report being generated by a computer system coupled to the graphical user interface, the computer system comprising:
one or more processor(s); and
one or more computer-readable hardware storage devices having stored thereon computer-executable instructions that are executable by the one or more processor(s) to cause the computer system to visually display the report.

### Claim 29 (depends on 27)

The method of claim 27, wherein each step of determining a respective CMS score comprises:
matching the expression level of each RNA transcript from a respective group of genetic elements with a reference expression level of said RNA transcript in a reference data set, each reference expression level corresponding to a scaled value representing the probability that the CMS of a colorectal cancer expressing said RNA transcript at said reference expression level is one of CMS1, CMS2, CMS3, and CMS4; and
calculating respective CMS scores based on the respective scaled values for each of the RNA transcripts from the respective group of genetic elements.

### Claim 30 (depends on 29)

The method of claim 29, wherein the reference data set comprises a curve fit of a population of the respective RNA transcript, the curve fit reflecting the probability that the CMS of a colorectal cancer expressing said RNA transcript at various reference expression levels is one of CMS1, CMS2, CMS3, and CMS4.

### Claim 31 (depends on 29)

The method of claim 29, wherein calculating the respective CMS scores comprises calculating a mean of the respective scaled values for each of the RNA transcripts from the respective group of genetic elements.

### Claim 32 (depends on 31)

The method of claim 31, wherein calculating the respective CMS scores comprises:
producing a first CMS pre-score that informs membership in CMS1 by ranking risk scores of genes by level of significance in predicting membership in CMS1 in the CMS1 reference data set; and
selecting at least three of the genes corresponding to at least three of the highest rank genes in the CMS1 reference data set that are also among the highest ranked genes in a second CMS1 reference data set;
calculating the second CMS score further comprises:
producing a second CMS pre-score that informs membership in CMS2 by ranking risk scores of genes by level of significance in predicting membership in CMS2 in the CMS2 reference data set; and
selecting at least three of the genes corresponding to at least three of the highest rank genes in the CMS2 reference data set that are also among the highest ranked genes in a second CMS2 reference data set;
calculating the third CMS score further comprises:
producing a third CMS pre-score that informs membership in CMS3 by ranking risk scores of genes by level of significance in predicting membership in CMS3 in the CMS3 reference data set; and
selecting at least three of the genes corresponding to at least three of the highest rank genes in the CMS3 reference data set that are also among the highest ranked genes in a second CMS3 reference data set;
calculating the fourth CMS score further comprises:
producing a fourth CMS pre-score that informs membership in CMS4 by ranking risk scores of genes by level of significance in predicting membership in CMS4 in the CMS4 reference data set; and
selecting at least three of the genes corresponding to at least three of the highest rank genes in the CMS4 reference data set that are also among the highest ranked genes in a second CMS4 reference data set.

### Claim 33

(canceled)

### Claim 34 (depends on 33)

The method of claim 33, wherein the treatment protocol specific for the colorectal cancer is determined by the stage of the cancer, the grade of the cancer, the metastatic state of the cancer, and the presence or absence of one or more genetic mutations in a patient tissue sample.

### Claim 35 (depends on 33)

The method of claim 33, wherein each step of obtaining an expression level of at least three RNA transcripts comprises:
extracting RNA transcripts from a colorectal cancer tissue sample from the cancer patient; and
quantifying the expression level of the at least three of the RNA transcripts.

### Claim 36 (depends on 35)

The method of claim 35, wherein the colorectal cancer tissue sample is a formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissue sample and wherein extracting RNA transcripts from the colorectal cancer tissue sample comprises extracting RNA transcripts from the formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissue sample.

### Claim 37

(canceled)

### Claim 38 (depends on 27)

The method of claim 27, wherein each CMS score comprises a number having a scaled value between 0 and 1 or between 0 and 100, or an equivalent thereof.

### Claim 39 (depends on 27)

The method of claim 27 further comprising applying a CMS classification protocol to determine the CMS of the colorectal cancer based on a plurality of CMS score, as follows:
(xvii) classifying the colorectal cancer with a CMS determination of CMS1 when the first CMS score and the fourth CMS score are each above respective predictive thresholds;
(xviii) classifying the colorectal cancer with a CMS determination of CMS4 when the second CMS score and the fourth CMS score are each above respective predictive thresholds and when (i) does not apply;
(xix) selecting from among the first, second, third, and fourth CMS scores a maximal CMS score and classifying the colorectal cancer with a CMS determination selected from the group consisting of CMS1, CMS2, CMS3, and CMS4 based on or corresponding to the maximal CMS score when the maximal CMS score is above the predictive threshold and when neither (i) nor (ii) applies;
(xx) classifying the colorectal cancer with a CMS determination of mixed subtype or unclassified subtype when the first, second, third, and fourth CMS scores are each below the predictive threshold.

### Claim 40 (depends on 27)

The method of claim 27, wherein the report further indicates one or more of:
the CMS determination;
the CMS of the colorectal cancer;
a treatment protocol based at least in part on the CMS determination; and
a treatment protocol specific for the CMS of the colorectal cancer.

### Claim at position 16

41-44. (canceled)

### Claim 45 (depends on 27)

The method of claim 27, wherein:
the at least three RNA transcripts from the first group comprise or consist of RNA transcripts of the genes represented by or corresponding to ENTREZ IDs 9219, 57168, 7105, 23475, and 998;
the at least three RNA transcripts from the second group comprise or consist of RNA transcripts of the genes represented by or corresponding to ENTREZ IDs 112858, 5326, 23509, 6780, and 1846;
the at least three RNA transcripts from the third group comprise or consist of RNA transcripts of the genes represented by or corresponding to ENTREZ IDs 7078, 80150, 84189, 84666, and 5937; and
the at least three RNA transcripts from the fourth group comprise or consist of RNA transcripts of the genes represented by or corresponding to ENTREZ IDs 143903, 23414, 11037, 27295, and 165

### Claim 46

A method of classifying a human colorectal cancer tumor into a consensus molecular subtype (CMS) based on a CMS score derived from an abbreviated gene expression profile, the method comprising:
obtaining an expression level of at least three RNA transcripts from a colorectal cancer tissue sample, the at least three RNA transcripts being selected from a first group of genetic elements that define a first CMS profile for one of CMS1, CMS2, CMS3, and CMS4;
determining, based on the expression level of each of the at least three RNA transcripts from the first group of genetic elements, a first CMS score representative of a probability that the CMS of the colorectal cancer corresponds with the CMS of the first CMS profile; and
classifying the colorectal cancer with a CMS determination corresponding to the CMS of the first CMS profile based at least in part on the first CMS score, wherein the first CMS score is above a predictive threshold.

### Claim 47 (depends on 46)

The method of claim 46 further comprising:
obtaining an expression level of at least three RNA transcripts selected from a second group of genetic elements that define a second CMS profile for one of CMS1, CMS2, CMS3, and CMS4 that is different from the CMS of the first CMS profile, the at least three RNA transcripts from the second group of genetic elements being from the colorectal cancer tissue sample; and
determining, based on the expression level of each of the at least three RNA transcripts from the second group of genetic elements, a second CMS score representative of a probability that the CMS of the colorectal cancer corresponds with the CMS of the second CMS profile.

### Claim 48 (depends on 47)

The method of claim 47, wherein the step of classifying the colorectal cancer with a CMS determination corresponding to the CMS of the first CMS profile is further based on the second CMS score.

### Claim at position 21

49-56. (canceled)

### Claim 57 (depends on 46)

The method of claim 46 further comprising generating a report indicating one or more of the CMS determination, the CMS of the colorectal cancer, a treatment protocol based at least in part on the CMS determination, and a treatment protocol specific for the CMS of the colorectal cancer.

### Claim 58 (depends on 46)

The method of claim 46, wherein determining a CMS score comprises:
matching the expression level of each RNA transcript with a reference expression level of said RNA transcript in a respective reference data set, each reference expression level corresponding to a scaled value representing the probability that the CMS of a colorectal cancer expressing said RNA transcript at said reference expression level is one of CMS1, CMS2, CMS3, and CMS4; and
calculating the CMS score based on the respective scaled values for each of the RNA transcripts.

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61 (depends on 46)

The method of claim 46, wherein the first group of genetic elements comprises a panel of genes expressed in a population of colorectal cancers having a CMS selected from CMS1, CMS2, CMS3, and CMS4.

### Claim at position 27

62-112. (canceled)
